MARKET

AXDX

AXDX

Accelerate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.97
-0.08
-1.32%
Closed 16:00 09/20 EDT
OPEN
5.93
PREV CLOSE
6.05
HIGH
6.06
LOW
5.86
VOLUME
129.23K
TURNOVER
--
52 WEEK HIGH
15.60
52 WEEK LOW
5.35
MARKET CAP
367.15M
P/E (TTM)
-4.1702
1D
5D
1M
3M
1Y
5Y
Return on Capital Employed Overview: Accelerate Diagnostics
After pulling data from Benzinga Pro it seems like during Q2, Accelerate Diagnostics (NASDAQ:AXDX) posted sales of $2.80 million. Earnings were up 12.17%, but Accelerate Diagnostics still reported an overall loss of $17.59 million.
Benzinga · 08/31 15:37
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
Benzinga · 08/23 09:06
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/06 00:35
BRIEF-Accelerate Diagnostics Q2 Loss Per Share $0.36
reuters.com · 08/05 22:08
Accelerate Diagnostics EPS misses by $0.03, misses on revenue
Accelerate Diagnostics (NASDAQ:AXDX): Q2 GAAP EPS of -$0.36 misses by $0.03. Revenue of $2.8M (+31.5% Y/Y) misses by $0.26M. Press Release
Seekingalpha · 08/05 20:20
Accelerate Diagnostics Reports Second Quarter 2021 Financial Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended .
PR Newswire - PRF · 08/05 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXDX. Analyze the recent business situations of Accelerate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXDX stock price target is 13.00 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 27.79M
% Owned: 45.19%
Shares Outstanding: 61.50M
TypeInstitutionsShares
Increased
25
748.02K
New
10
86.61K
Decreased
31
932.54K
Sold Out
16
466.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.76%
Healthcare Equipment & Supplies
-1.59%
Key Executives
Chairman/Independent Director
John Patience
President/Chief Executive Officer/Director
John Phillips
Chief Financial Officer
Steve Reichling
Other
Ron Price
Director
Hany Massarany
Independent Director
Thomas Brown
Independent Director
Louise Francesconi
Independent Director
Mark Miller
Independent Director
Jack Schuler
Independent Director
Matthew Strobeck
Independent Director
Frank Ten Brink
Independent Director
Charles Watts
No Data
  • All
  • Financials
  • Insiders
More
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Webull offers kinds of Accelerate Diagnostics Inc stock information, including NASDAQ:AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.